Press Releases IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Real-time Estimate Cboe BZX Other stock markets 02:38:39 2024-04-29 pm EDT			5-day change	1st Jan Change
10.03 ^USD	+6.70%		+49.70%	+21.60%

Apr. 17	IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	MT
Apr. 17	IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IGM Biosciences Announces Refocusing of Sanofi Collaboration	Apr. 17	GL
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum	Apr. 10	GL
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 07	GL
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 07	AQ
MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2023	Feb. 15	AQ
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	GL
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	AQ
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway	Dec. 06	AQ
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension	Dec. 05	GL
Bulletin from Extraordinary General Meeting in Medivir AB (publ)	Dec. 01	PR
Medivir to present at the Erik Penser Bank Company Event	Nov. 21	PR
IGM Biosciences Announces Third Quarter 2023 Financial Results	Nov. 13	GL
IGM Biosciences to Present at Two Upcoming Investor Conferences	Nov. 07	GL
Change in Medivir's Board of Directors	23-10-23	AQ
Medivir AB - Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles	23-10-06	AQ
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles	23-10-05	PR
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors	23-10-03	GL
Medivir s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase clinical Study	23-09-12	AQ
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	23-09-06	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Press Releases

Filters